Genprex, Inc. — Director's Dealing 2025

Dec 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Genprex, Inc. (GNPX)
CIK: 0001595248
Period of Report: 2025-12-22

Reporting Person: Berger Mark Stanley (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-22	Common Stock	A	28500	—	Acquired	28860	Direct

Footnotes

F1: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.